Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: gene mutations occur in 2 to 4% of patients with non-small-cell lung cancer (NSCLC). Sevabertinib is an oral, reversible tyrosine kinase inhibitor that has shown anti-HER2 activity in preclinical models. METHODS: -mutant NSCLC. Three cohorts were defined according to previous therapy: cohort D comprised previously treated patients who had not received HER2-targeted therapy; cohort E, patients who had previously received HER2-directed antibody-drug conjugates; and cohort F, patients who had not previously received treatment. The primary end point was an objective response, as assessed by blinded independent central review. Secondary end points were duration of response and progression-free survival. RESULTS: A total of 209 patients received sevabertinib (as of June 27, 2025, the data-cutoff date); the median duration of follow-up was 13.8 months in cohort D, 11.7 months in cohort E, and 9.9 months in cohort F. Among 81 patients in cohort D, an objective response was observed in 64% (95% confidence interval [CI], 53 to 75); the median duration of response was 9.2 months (95% CI, 6.3 to 13.5), and the median progression-free survival was 8.3 months (95% CI, 6.9 to 12.3). Among 55 patients in cohort E, an objective response was observed in 38% (95% CI, 25 to 52); the median duration of response was 8.5 months, and the median progression-free survival was 5.5 months. Among 73 patients in cohort F, an objective response was observed in 71% (95% CI, 59 to 81), and the median duration of response was 11.0 months; data on progression-free survival were immature. Grade 3 or higher drug-related adverse events occurred in 31% of the patients. The most common adverse event was diarrhea (in 84 to 91%), with diarrhea of grade 3 or higher occurring in 5 to 23%. Treatment was discontinued by 3% of the patients owing to drug-related adverse events. CONCLUSIONS: -mutant NSCLC. Diarrhea was the most common adverse event. (Funded by Bayer; SOHO-01 ClinicalTrials.gov number, NCT05099172.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paik, P. K., Felip, E., Veillon, R., Sakai, H., Cortot, A. B., Garassino, M. C., Mazieres, J., Viteri, S., Senellart, H., Van Meerbeeck, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004407 · Cited by 870
Self-citationHER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556
Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S.-W., Planchard, D., Ahn, M.-J., Smit, E. F., de Langen, A. J., Pérol, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01361 · Cited by 328
Self-citation
Cited by
Puri, S., Leighl, N. B., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02822 · Cited by 46
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Heymach, J. V., Yamamoto, N., Girard, N., Ruiter, G., Smit, E. F., Planchard, D., Nadal, E., Wu, Y.-L., Zugazagoitia, J., Tu, H., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2516969 · Cited by 23
Self-citationNitrogen-containing FDA-approved drugs in 2025: synthesis, significance and therapeutic applications
Chetna, J., Mishra, S., Potuganti, G. R., Cardoza, S., & Velma, G. R. (2026) · RSC Advances · doi:10.1039/d6ra00737f · Cited by 18
Tiz, D. B., D’Alì, M., Iraci, N., Santi, C., & Sancineto, L. (2026) · Biomolecules · doi:10.3390/biom16030381 · Cited by 15
Stockhammer, P., Zarif, T. E., Schillo, J. L., Li, F., Goldberg, S. B., Politi, K. A., & Grant, M. J. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103708 · Cited by 5
Emerging Targeted Therapies for HER2-Mutant NSCLC
Rio, B. D., Masini, S., Cáceres-Galvis, C., Torres-Jiménez, J., Bote, H., Berjaga, M. Z., Baena-, J., Serrano, C., Nuñez, J. A., Ponce-Aix, S., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103899 · Cited by 5
HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape
Muscolino, P., Fassi, E., Signorelli, D., Colonese, F., Cortinovis, D. L., Russo, G. L., Pasello, G., Infurna, C., Ciappina, G., Berretta, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052334 · Cited by 3
“In contrast, in patients without BMs at baseline, post-baseline brain progression occurred in 6% of cohort D, 5% of cohort E, and 3% of cohort F. Diarrhea was the most common adverse event (reported in 84–91% of patients), with grade ≥ 3 events observed in 5–23% of patients [58].”
Keam, S. J. (2026) · Drugs · doi:10.1007/s40265-026-02299-w · Cited by 3
Synthesis and Clinical Application of Small‐Molecule Drugs Approved by FDA in 2025
Chang, L., Wang, M., Zhang, H., Li, Z., Song, Z., Zhao, L., Jiang, F., Wang, J., & Yuan, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70064 · Cited by 5
“…Phase 1/2 SOHO‐01 trial (NCT05099172) demonstrated significant clinical efficacy, with objective response rates up to ~71% and median duration of response ~9.2 months in previously treated, HER2‐mutant NSCLC patients and manageable toxicity primarily consisting of diarrhea, rash, and nausea [45].”
InfluentialTiz, D. B. (2026) · Medicines · doi:10.3390/medicines13030022 · Cited by 8
Expanding targeted therapy for lung cancer
Ballard, W., Agarwal, M., & Liu, S. V. (2025) · Nature Cancer · doi:10.1038/s43018-025-01083-1 · Cited by 2
Evolving treatment strategies for HER2-altered non–small-cell lung cancer: the rise of TKIs and ADCs
Ballı, S., Başoğlu, T., & Ozdogan, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771869 · Cited by 5
“Toxicities were manageable (mostly grade 1 – 2 diarrhea and rash), and importantly, no interstitial lung disease was observed (65).”
Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer
Kim, J., & Ahn, M. (2026) · Future Oncology · doi:10.1080/14796694.2026.2658641 · Cited by 2
“Sevabertinib demonstrated ORRs of 64% in previously treated HER2-therapy-naïve patients and 38% in patients treated after prior HER2 ADCs with an acceptable safety profile [36].”
InfluentialRuiter, G., Le, X., Soo, R. A., Yamamoto, N., Girard, N., Wu, Y.-L., Sabari, J. K., & Nadal, E. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109378 · Cited by 1
Self-citationLess Is More, But Me-Too Should Not Be the Strategy for Lung Cancer Treatment in 2026
Bortolot, M., Saw, S. P. L., Pietroluongo, E., Govind, R., Patel, A., Garassino, M. C., & Remón, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517100 · Cited by 1
Harada, G., Chaft, J. E., Schram, A. M., Pavlakis, N., & Wu, Y.-L. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103137 · Cited by 1
Tanvetyanon, T., Chen, D.-T., & Gray, J. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093481 · Cited by 1
Goto, K., Hayashi, H., Maruti, S. S., Zettl, H., Mittal, L., Pathak, S., & Le, X. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01213-4 · Cited by 1
“In 2025, the HER2-selective tyrosine kinase inhibitor (TKI) zongertinib [10–12], and the HER2/EGFR TKI, sevabertinib [13, 14], received FDA accelerated approval on the basis of the Beamion LUNG-1 and SOHO-01 trials [10, 14].”
Self-citationHER2 Therapies in Non-Small Cell Lung Cancer (NSCLC)
Meinhardt, F. W. R., Iglesias, M. I. Z., Gómez, M. P. F., Fonseca, J. F. S., Hussein, A., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114910 · Cited by 1
“Notably, no cases of ILD or pneumonitis were reported (Table 1) [55].”
Lovly, C. M., Baik, C., Nagasaka, M., Patil, T., Maruti, S. S., Stanhope, S. A., Kaya, N. A., Herbertz, S., Nordstrom, B., Evans, K., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01272 · Cited by 2
“15,17 Zongertinib is also approved in China (conditional) and Japan for patients with previously treated advanced/metastatic HER2 -mutant NSCLC. 19-30 However, some lacked detailed genomic pro fi ling, assessment of clinical outcomes according to line of treatment (LOT), and survival data.”
Self-citationResearch progress of small molecule targeted drugs for non-small cell lung cancer
Qiu, T., & Huang, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1847493 · Cited by 1
“Only 3% of patients discontinued treatment due to TRAEs (233).”
Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies
Hendriks, L. E. L., Lin, J. J., Tan, D. S. W., Acker, F., Ogliari, F. R., Meyer, M., Planchard, D., & Reck, M. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00253-5 · Cited by 2
Self-citationSmall-Molecule Drugs Approved by the FDA in 2025
Wang, X., Wang, Y., Luo, R., 牛东海, Yang, L., & Wang, Z. (2026) · Molecules · doi:10.3390/molecules31193447 · Cited by 1
Gulden, J. (2025) · Deutsches Ärzteblatt · doi:10.3238/persesmo.2025.11.28.04
Evangelou, C. (2025) · Oncology The American Medical Journal · doi:10.33590/oncolamj/befa1660
Actualités 2025 par le comité de rédaction du Bulletin du Cancer : congrès ASCO, ESMO et au-delà
Vignot, S., Bellesœur, A., Borchiellini, D., Bouleuc, C., Cohen, R., de Nonneville, A. T., Delom, F., Évrard, S., Firmin, N., Gandemer, V., et al. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.12.001
(2025) · Oncology Times · doi:10.1097/01.cot.0000000000000277
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Wu, L., Yu, J., & Liu, W. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2517517 · Cited by 1
Self-citationHuang, X. S., Yu, W., Li, X., Cai, B., Qu, B., Chen, J., Zhang, P., Chen, X., Liu, Y., Feng, S., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1727362
“Recently, the FDA approved two HER2 kinase inhibitors, sevabertinib and zongertinib, for the treatment of NSCLC patients with HER2 tyrosine kinase domain (TKD) activating mutations (36, 37).”
Zongertinib and Sevabertinib for Her2-Mutant Non-Small Cell Lung Cancer
Sunny, G., Basu, P., & Yadav, R. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1817162
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer
Fortman, D. D., & Qin, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1750153 · Cited by 2
“…with sevabertinib showing promising results in the phase I-II SOHO-01 clinical trial (NCT05099172) for HER2 -mutated disease, leading to its accelerated FDA approval in November 2025 (190); this agent is also being studied as front-line therapy in the ongoing phase III SOHO-02 trial (NCT06452277).”
Scaglione, I. M., Bonato, A., Dodi, A., Sposito, M., Eccher, S., Avancini, A., Tregnago, D., Insolda, J., Milella, M., Pilotto, S., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062643 · Cited by 1
“Similarly, the SOHO-01 trial supports HER2-targeted TKI therapy with sevabertinib, showing an ORR of up to 71% in treatment-naïve patients and 64% in pretreated patients, with a median response duration of approximately 8.5–11 months [56].”
InfluentialTrendbericht Organische Chemie 2026
Breugst, M., Andexer, J. N., Barra, L., Beil, S. B., Bierbach, S., Burkhardt, I., Dumele∞, O., Ernst, M., Frommer, J., Gellrich, U., et al. (2026) · Nachrichten aus der Chemie · doi:10.1002/nadc.20264156596
Ishida, M., Yamada, T., Katayama, Y., Kawachi, H., Sawada, R., Nakamura, R., Hirai, S., Matsui, Y., Morimoto, K., Onoi, K., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01385-2 · Cited by 1
“Sevabertinib (BAY 2927088), a reversible HER2-TKI targeting HER2 exon 20 insertion mutations, also demonstrated substantial antitumor activity in advanced HER2-mutant NSCLC in the SOHO-01 trial and similarly received U.S. FDA breakthrough therapy designation 16 .”
Kashizaki, F., Orii, R., Watanabe, S., & Yumoto, K. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.03.018
Metastasiertes nichtkleinzelliges Lungenkarzinom mit Treiberalterationen
Frille, A. (2026) · Zeitschrift für Pneumologie · doi:10.1007/s10405-026-00673-9
Non-small cell lung cancer in 2026: A narrative review of clinical advances and systemic challenges
Frey, C. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100010
Nagasaka, M., Arter, Z., Park, C. H., Sarkari, A., & Ou, S. I. (2026) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s600499
Nagl, L., Horvath, L., Amann, A., Schreiner, L., Günther, M., Maier, H., Kerschbaumer, J., Widmann, G., Minasch, D., Rossetti, L.-M., et al. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.101023 · Cited by 1
Reinhorn, D. J., Kuten, J., Preeshagul, I. R., Eng, J., Ng, K., Drilon, A., Chaft, J. E., Santini, F. C., & Awad, M. M. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.101024
“28,29 Therefore, TKIs might offer superior efficacy post-T-DXd compared with T-DM1.”
Practice‐Changing Advances in Systemic Therapies Shaping the Landscape of Lung Cancer in 2025
Zhou, Z., Gao, W., Li, M. S. C., & Zhou, Q. (2026) · Cancer Innovation · doi:10.1002/cai2.70064
Drugs that boost immunity are making lung cancer less deadly
Worth, T. (2026) · Nature · doi:10.1038/d41586-026-01455-2
Chen, M., Gandhib, J., Wu, S., & Cheng, H. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2691245
Scudamore, O., Wind, S., Grempler, R., Esmaeili, H., & Müller, F. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70182
“Other HER2-directed agents have been granted accelerated approval in the United States for patients with previously treated advanced HER2 - mutant NSCLC, including the antibody–drug conjugate trastuzumab deruxtecan [10] and the EGFR/HER2 TKI sevabertinib [11].”
Elantably, D., Meerzaman, I., Hou, A. Y., Abdelhakeem, A., & Lou, Y. (2026) · Cancers · doi:10.3390/cancers18132121
“…SqCLC represent an important therapeutic gap as currently FDA-approved HER2-selective tyrosine kinase inhibitors (TKIs), including zogertinib and sevabertinib, were developed primarily for TKD-mutant non-squamous NSCLC and have showed limited and inconsistent activity in non-TKD mutations [33,34].”
InfluentialBagde, P. H., Deb, B., Shrivastava, H., & Jha, H. C. (2026) · Springer eBooks · doi:10.1007/978-981-95-9777-2_13
Decoster, L., Aftimos, P. G., Rottey, S., Prenen, H., Collignon, J., Mebis, J., Canon, J. L., Fastenaekels, V., Cappoen, N., Kondrat, A., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01198
The Evolving Role of Bispecific Antibodies in Oncogene-Driven NSCLC
Wang, J. C., Rosas, D., & Raez, L. E. (2026) · Cancers · doi:10.3390/cancers18142197
Zullo, L., & Remón, J. (2026) · Cancers · doi:10.3390/cancers18142334
“%) patient treated with sevabertinib 10 mg/die in cohort D1 [94].”
InfluentialNassar, A. H., Halawi, J., & Herbst, R. S. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000834
Medical Management of Non–Small Cell Lung Cancer Brain Metastases in the Modern Era
Lu, B. Y., & Goldberg, S. B. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000840
Management of brain metastases in older adults with non–small cell lung cancer
Lopes, J. B., Schep, D. G., Sahgal, A., Rodrigues, R. F., & Menjak, I. B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1858724
“Data from cohort G evaluating active brain metastases are pending publication (144, 145).”
HER2 mutation–derived neoantigens in NSCLC as actionable targets for TCR therapyPreprint
Montoya, A., Nie, H., Jiang, P., Slone, J. K., Shulga, Y. V., Patel, A., Menon, P. S., Polic, I., Bontekoe, E., Hong, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.30.741830
Self-citationLi, X., Qi, K., Ou, S. I., & Hu, Y. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103943
Wang, Q., Wen, J., Zeng, B., You, C., Chen, X., Ye, J., Xu, T., Yang, X., Chen, J., Zhou, G., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1925627
Neuer reversibler TKI bei HER2-mutiertem NSCLC
(2026) · Pneumologie · doi:10.1055/a-2761-2703
Yang, Y., Jiang, W., Yang, G., Li, W., Li, J., Hao, X., Xing, P., Lei, S., Wei, F., Tian, L., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109589
Zongertinib to Target HER2-Driven Resistance in EGFR Mutation-Positive NSCLC: A Case Report
Torres-Jiménez, J., Serrano‐Gómez, C., Baena, J., Bote, H., Zurera-Berjaga, M., Martín, A. L., Ponce-Aix, S., Paz-Ares, L. G., & Zugazagoitia, J. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.08.010
Role of CYP3A4 in the metabolism of tyrosine kinase inhibitors in non–small cell lung cancer therapy
Sultana, S., Kamal, M., Chen, H., & Li, W. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100394
Antibody–Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges
Paliogiannis, P., Fara, G., Zinellu, A., Fois, A. G., & Palmieri, G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48090868
“Whether ADCs should be administered sequentially, combined with targeted therapies, or reserved for specific resistance settings remains an important clinical question that will require prospective randomized evaluation [165,166].”
Matsumura, N. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03190-0
Litkowska, A., Wojtas, J., Nadulska, K., Kurec, G., Burdan, O., & Krawczyk, P. A. (2026) · Genes · doi:10.3390/genes17091076
“…HER2 TKIs—such as zongertinib and sevebertinib—have emerged as highly potent oral agents that selectively target HER2 exon 20 insertions and kinase https://doi.org/10.3390/genes17091076 domain mutations while sparing wild-type EGFR, significantly reducing EGFR-related toxicities [10,15,50,51].”
InfluentialInnovative therapies for HER2-altered non-small cell lung cancer: A narrative review
Arrieta, O. G., Caballé‐Perez, E., Cabrera-Miranda, L. A., Cardona, A. F., Davila-Dupont, D., Velasco-Córdoba, M., & Treviño, L. A. C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105619
Li, M. S. C., Soon, Y. Y., Au-Yeung, P. Y., Chan, A. L. S., Lee, J.-B., Nützinger, J., Tateishi, A., & Ross, S. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.106129
Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer
Rabinovich, E. P., & Martin, L. W. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197644
“Activating HER2 TK domain mutations occur in approximately 2–4% of NSCLC, arising predominantly in adenocarcinomas, never-smokers, and women [37].”
Genomic Landscape and Clinical Actionability of Skin Adnexal Carcinomas
Filho, V. O. C., Noronha, M. M., Passos, P. R. C., Lopes, C. D. H., Leite, G. G. F., Maia, D. C. C., Wanderley, C. W. S., Saibil, S. D., & Saldanha, E. F. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00300
Le, X., Wang, J., Yu, Y., Zhao, Y., Planchard, D., Gao, B., Spira, A. I., Liu, J., Li, X., Gadgeel, S. M., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.09.011 · Cited by 1
Self-citationRole of maintaining the TKI backbone in oncogene-driven NSCLC after progression
Piazza, F., Sharma, R., Esposito, A., Siniscalchi, C., Sacco, M., Moscvin, M., Wu, S., Sangaletti, S., Rizvi, N., Behera, V., et al. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103235
Pan-Gynecologic Cancer Analysis of ERBB2 Gene Mutations Across More Than 21,000 Tumor Samples
Ahsan, M. D., Gysler, S. M., Ko, E., Guintoli, R. L., Kim, S. H., Latif, N., & Nasioudis, D. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.105679
Zhang, T., Tan, C., Sun, H., Gu, W., Wang, W., Xu, M., & Sheng, W. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00850-9
Metadata
- Authors
- Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., Shinno, Y., Daniele, G., Yang, T.-Y., Kim, H. R., Ruiter, G., Zhao, J., Novello, S., Miao, L., Jänne, P. A., Goto, K., Rüttinger, D., Descamps, T., Brase, J. C., Bao, W., Li, R., Brega, N., Grassi, P., Girard, N., & Tan, D. S.-W.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Seoul National University (KR)
- Chinese University of Hong Kong (HK)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- National University of Singapore (SG)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sir Run Run Shaw Hospital (CN)
- Shanghai Jiao Tong University (CN)
- Wuhan Union Hospital (CN)
- Central South University (CN)
- National Cancer Center Hospital (JP)
- Agostino Gemelli University Polyclinic (IT)
- Taichung Veterans General Hospital (TW)
- Yonsei University (KR)
- The Netherlands Cancer Institute (NL)
- Peking University Cancer Hospital (CN)
- Ospedale San Luigi Gonzaga (IT)
- Nanjing Drum Tower Hospital (CN)
- Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute, Boston
- National Cancer Center Hospital East, Kashiwa, Japan
- Bayer (Germany) (DE)
- Bayer (United Kingdom) (GB)
- Bayer (Switzerland) (CH)
- Bayer (United States) (US)
- Bayer (Italy) (IT)
- Institut Curie (FR)
- ORCID
- Le, Xiuning
- Kim, Tae Min
- Loong, Herbert H.
- Prelaj, Arsela
- Goh, Boon Cher
- Li, Lin
- Lu, Shun
- Dong, Xiaorong
- Wu, Lin
- Shinno, Yuki
- Daniele, Gennaro
- Kim, Hye Ryun
- Ruiter, Gerrina
- Zhao, Jun
- Novello, Silvia
- Miao, Liyun
- Rüttinger, Dominik
- Descamps, Tine
- Brase, Jan Christoph
- Li, Rui
- Brega, Nicoletta
- Grassi, Paolo
- Girard, Nicolas
- Tan, Daniel Shao-Weng
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-11-06
- Volume
- 393
- Issue
- 18
- Pages
- 1819-1832
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4415295860
- Cited by
- 70
- References
- 34
- Citations by year
- 2026: 65 · 2025: 5
- FWCI
- 45.69
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- HER2-mutant non-small cell lung cancer, HER2 tyrosine kinase inhibitor, HER2-targeted therapy, antibody-drug conjugates, objective response rate, progression-free survival, diarrhea adverse event, advanced non-small cell lung cancer, oral tyrosine kinase inhibitor, previously treated patients, treatment-naive patients, duration of response, treatment discontinuation
- MeSH terms
- Progression-Free Survival, Tyrosine Kinase Inhibitors, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Diarrhea, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Time Factors, Erb-b2 Receptor Tyrosine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.